Research opens new doors to treating glaucoma

By Jan Jarvis

Dr. Zode
Gulab Zode, PhD, with Ramesh Kasetti, PhD, in the lab at UNTHSC.

Glucocorticoids are often used to reduce inflammation, reduce pain and treat many conditions such as allergies and rashes. But for some people, the very drugs that treats one condition can cause another: specifically, glaucoma.

The condition, which affects more than 64.3 million people, is the second-leading cause of irreversible blindness in the world. Still, little is known about why glucocorticoid therapy elevates intraocular pressure and raises the risk of developing this disease, said Gulab Zode, PhD, Assistant Professor in Pharmacology & Neuroscience.

“We know that when people are treated with glucocorticoids, one of the possible side effects is increased intraocular pressure,” he said. “About 30 percent to 40 percent of patients develop this and if they don’t get treated, they experience vision loss.”

In a paper recently published in the Journal of Biological Chemistry, a team of scientists led by Dr. Zode discovered how glucocorticoids elevate intraocular pressure in the eye.

“There are no treatments that target the pathology of this disease, there are only drugs that act on the symptoms,” he said, “I want to know what causes the damage so that a targeted treatment could be developed.”

For years, Dr. Zode’s research has focused on what causes damage to the trabecular meshwork, a specialized tissue in the eye that maintains normal intraocular pressure by regulating aqueous humor outflow resistance.

In this article, Dr. Zode’s lab identified that glucocorticoids increase the transforming growth factor B2, which further contributes to elevation of intraocular pressure. The study establishes a central role for transforming growth factor B2 in glucocorticoid-induced glaucoma and provides therapeutic targets for the reduction of increased intraocular pressure in the eye.

“Now that we can see how transforming growth factor B2 plays a role in intraocular pressure elevation, we can block this signaling pathway,” he said. “This opens the door to the possibility of targeted treatment.”

Recent News

7281bfad 8597 4cef 80de B58ea8a26ab5
  • Community
|Jun 10, 2024

North Texas Asthma Summit to improve asthma outcomes for children

Representatives from 10 North Texas organizations will come together Wednesday with one common goal in mind: improving health outcomes for children with poorly controlled asthma. The goal of the North Texas Asthma Summit is to develop community partnerships to help these children who frequently e...
Dobbs Headshot
  • Our People
|Jun 7, 2024

School of Health Professions welcomes three new staff members

The University of North Texas Health Science Center at Fort Worth’s School of Health Professions is excited to announce three new staff members in the dean’s office. Christa Lo, DHSc, MPAS, PA-C, joins SHP as associate dean. In her role, she will assist in overseeing the school’s academic...
Drwhite
  • Our People
|Jun 6, 2024

TCOM Alumnus Dr. Frederick White receives the Gold Medal Award for Distinguished Service from the AOCR

In recognition of his outstanding leadership, dedication and service, Frederick E. White, DO, FAOCR, a 1977 graduate from the Texas College of Osteopathic Medicine at The University of North Texas Health Science Center at Fort Worth, was selected as the recipient of the American Osteopathic College ...
Hampton 5
  • On Campus
|Jun 5, 2024

Hampton University representatives visit HSC to build partnerships

A delegation of five representatives from Hampton University visited The University of North Texas Health Science Center at Fort Worth’s campus on Friday. Hampton University is a private, historically Black university founded in 1868 in Hampton, Virginia. The group included President of Ham...